SAN DIEGO--(BUSINESS WIRE)--
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, will present at seven events in May. The company’s itinerary includes a number of prominent scientific and investment conferences, culminating in a presentation at the 2014 ASCO Annual Meeting.
PEGS: The Essential Protein Engineering Summit
Robert Pierce, M.D., Chief Medical Officer, will present a discussion titled, “Glass Half-Empty or Half-Full? Potential Mechanisms of Non-Response to Immunomodulatory Antibodies” at the 10th Annual Protein and Antibody Engineering Summit (PEGS), on May 5th, at 11:10 a.m. EDT, at Seaport World Trade Center in Boston, MA.
‘PEGS: The Essential Protein Engineering Summit’ will attract over 1800 attendees to Boston’s lively seaport district to participate in a variety of open forum discussions and collaborative affairs. This year’s summit will feature 20 conferences and 15 short courses. Dr. Pierce’s discussion will be a part of the Cambridge Healthtech Institute’s 4th Annual Antibodies for Cancer Therapy conference. For more information, please visit http://www.pegsummit.com
10th Annual EADO Congress: Advances in Diagnosis and Treatment of Skin Tumors
Axel Hauschild, M.D., Ph.D., Melanoma Advisory Board Member, will present at the 10th Annual European Association of Dermato-Oncology (EADO) Congress, to be held May 7th – 10th, 2014, in Vilnius, Lithuania.
EADO Congress is a stimulating and well-established annual affair that attracts top clinicians and researchers from around the world to share and review the most current data and practical information in the field of skin cancer. International key opinion leaders will present and report on the latest clinical trial results and discuss promising new treatments during the plenary lectures and symposia, and attendees will find the state of the art in prevention, early detection, innovative diagnostic, imaging, and treatment techniques for cutaneous malignancies. For more information, please visit: http://www.eado2014.com
Boston Biotech: Cancer Advance New York
Punit Dhillon, President and CEO, will be part of a discussion titled, “Cancer in 15 Years: Predictions,” at Boston Biotech Cancer Advance New York, on May 14, 2014 at 4:40 p.m. EDT, at Apella, an event space in Alexandria Center in New York City, NY.
Cancer Advances will bring together some of the most distinguished cancer experts from academia and industry, alongside biotech entrepreneurs, venture capitalists, buysiders, bankers and analysts, to participate in a high-energy, uniquely interactive meeting. Boston Biotech hosts exclusive thought-leader forums for senior bio-pharma executives. Each conference is highly interactive and meant to facilitate discussion, information sharing, networking, and corporate development among healthcare industry leaders. For more information, please visit: http://bbbiotechconference.com/conference-details.php?id=23
American Society of Gene and Cell Therapy (ASGCT) 17th Annual Meeting
Richard Heller, Ph.D., Scientific Advisory Board Member, will present a discussion titled, “Non-Viral Gene Transfer of pIL-12 for the Treatment of Melanoma: Results from Phase I and II Clinical Trials” at the ASGCT 17th Annual Meeting, to be held May 21-24, 2014 at the Marriott Wardman Park in Washington D.C.
The American Society of Gene and Cell Therapy’s Annual Meeting is designed to bring together scientists, physicians, patient advocates, and other stakeholders to facilitate the transformation of medicine by incorporating the use of genetic and cellular therapies to control and cure human disease. Dr. Heller’s discussion will be part of Scientific Symposium 213: Physical Gene & Cell Therapy and Vector Development, taking place in the Delaware AB room on May 22, 2014 from 10:15 a.m. – 12:15 p.m. EDT. For more information, please visit: http://www.asgct.org
Marcum MicroCap Conference
Punit Dhillon, President and CEO, will present a corporate overview of the company at the 3rd Annual Marcum MicroCap Conference, to be held at the Grand Hyatt New York in New York City on May 29, 2014. The invitation-only event attracts top fund managers and qualified high net worth investors, and will feature presentations from CEO’s and CFO’s of promising high-growth companies. For more information, please visit: http://www.marcumllp.com/microcap
American Cancer Society Blossom Ball
Punit Dhillon, President and CEO, will provide the Key Note address at the American Cancer Society’s Blossom Ball, to be held at Southridge Estates in Sutter, CA, on May 31, 2014. OncoSec Medical is proud to serve as Title Sponsor of this premier gala event, which will feature a silent auction, a gourmet dinner provided by New Hock Farm, and conclude in a night of dancing and live entertainment by the band JumpStart. For more information, please visit: http://main.acsevents.org
American Society of Clinical Oncology (ASCO) 50th Annual Meeting
Adil Daud, M.D., Chief Clinical Strategist, will present an abstract titled, “Systemic anti-tumor effect and clinical response in a phase 2 trial of intratumoral electroporation of plasmid interleukin-12 in patients with advanced melanoma” (ASCO Abstract #9025), at the 2014 ASCO Annual Meeting, to be held May 30-June 3, 2014 at McCormick Place in Chicago, Illinois. The abstract, which highlights unreleased data from the company’s Phase 2 study investigating the use of ImmunoPulse in patients with metastatic melanoma, will be part of the Poster Highlights Session: Melanoma and Skin Cancers, taking place June 2, 2014. For more information, please refer to the ASCO iPlanner: https://iplanner.asco.org/AM2014
ASCO 2014 will bring together over 25,000 oncology professionals from a wide range of specialties to explore this year’s theme – “Science and Society.” Attendees will have access to cutting-edge scientific presentations and comprehensive educational content that reflect ASCO’s dedication to providing the highest-quality resources in education, policy, the pioneering of clinical research, and the advancement of care for patients with cancer. For more information, please visit: http://www.asco.org
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its ImmunoPulse immunotherapy to treat solid tumors. OncoSec Medical’s core technology leverages a proprietary electroporation platform to enhance the local delivery and uptake of IL-12 and other DNA-based immune-modulating agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec’s clinical programs currently include three Phase 2 trials targeting metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma (http://clinicaltrials.gov/ct2/results?term=oncosec&Search=Search). As the company continues to evaluate ImmunoPulse in these indications, it is also investigating additional indications and combination therapeutic approaches. For more information, please visit www.oncosec.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
- Health Care Industry
Veronica Vallejo, CFO